about
Case report of malignant pulmonary parenchymal glomus tumor: imaging features and review of the literatureImpact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?Atypical presentation of Legionella pneumonia among patients with underlying cancer: A fifteen-year review.Imaging of thoracic cavity tumors.Radiogenomic evaluation of lung cancer - Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations?Preoperative computed tomography findings predict surgical resectability of thymoma.Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibitionMutations and PD-1 Inhibitor Resistance in -Mutant Lung AdenocarcinomaPostoperative complications after thoracic surgery for lung cancerResponse to ERBB3-Directed Targeted Therapy in NRG1-Rearranged CancersSafety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLCCirculating tumor DNA analysis to assess risk of progression after long-term response to PD-(L)1 blockade in NSCLCAfatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyA Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
P50
Q36395587-B8924256-BF3B-4742-9FE9-A48BA8A4D425Q36598758-24EA4AF7-22F7-472B-A0ED-80D2E3985F16Q37003218-497EC446-8B7B-4BF3-AD6B-587206965734Q37078573-8D9E1E7F-FDA9-40D9-A5C4-3FCAE85E85D8Q38253294-04787145-D186-4664-944E-D3EE023EE0A4Q40409078-24BCF15A-5F51-4594-B306-C929A8C73C4AQ53063099-7760B053-6924-4920-8026-C1ED33A03218Q56892343-BE6B3DA9-26D9-4D6D-B016-25CE9198AE53Q57232070-02458B50-ACEF-4314-9141-B70664881ADBQ85481620-2BFB288C-F334-4D87-8684-870B234DBD92Q88248409-4D3C5385-A064-4F11-97D6-37D289E9DBFCQ89506800-6BCFE2BE-B1C3-45D4-8994-E376172B83A8Q89663309-DFED78A8-BBCF-42B8-AA5F-35AACD21B8EFQ91238323-1120FC63-6C7D-4B61-9130-97CCEB731E52Q92525811-DFB8E26E-C6C5-4334-B1B6-74A1688849F2
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-3772-370X
@en
name
Andrew J Plodkowski
@ast
Andrew J Plodkowski
@en
Andrew J Plodkowski
@es
Andrew J Plodkowski
@nl
type
label
Andrew J Plodkowski
@ast
Andrew J Plodkowski
@en
Andrew J Plodkowski
@es
Andrew J Plodkowski
@nl
prefLabel
Andrew J Plodkowski
@ast
Andrew J Plodkowski
@en
Andrew J Plodkowski
@es
Andrew J Plodkowski
@nl
P106
P31
P496
0000-0002-3772-370X